Welcome to our dedicated page for Gain Therapeutics news (Ticker: GANX), a resource for investors and traders seeking the latest updates and insights on Gain Therapeutics stock.
Gain Therapeutics, Inc. (Nasdaq: GANX) is a clinical-stage biotechnology company whose news flow is closely tied to the development of its lead drug candidate, GT-02287, and to progress in its broader allosteric small molecule pipeline. The company focuses on next generation allosteric therapies targeting neurodegenerative diseases, rare genetic disorders and oncology, with a primary emphasis on Parkinson’s disease.
News about Gain Therapeutics frequently covers clinical milestones for GT-02287, including updates from its Phase 1 and Phase 1b studies in people with Parkinson’s disease with or without a GBA1 mutation. Press releases have detailed safety and tolerability findings, exploratory biomarker data such as reductions in glucosylsphingosine (GluSph) in cerebrospinal fluid, and observations related to Movement Disorder Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) scores. These items provide insight into how the company interprets GT-02287’s potential disease-modifying effects and mechanism of action.
Investors and observers can also expect regular announcements on preclinical research and scientific presentations. Gain Therapeutics reports data from preclinical models that explore GCase modulation, mitochondrial and lysosomal health, and neuroprotection in Parkinson’s disease. Poster presentations at scientific meetings, such as Neuroscience conferences and Parkinson’s-focused congresses, are common subjects of the company’s news releases.
Additional news items include corporate updates and financial disclosures, such as quarterly financial results, capital raises, changes in board composition, and shareholder meeting outcomes. The company also issues notices about participation in investor conferences, key opinion leader (KOL) events, and webinars that discuss biomarkers, clinical endpoints and emerging data from GT-02287 studies.
For readers following GANX, the news page provides a centralized view of clinical trial progress, scientific data, regulatory and corporate developments, and event participation related to Gain Therapeutics’ efforts in allosteric small molecule drug development.
Gain Therapeutics, Inc. (Nasdaq: GANX) announced that CEO Eric Richman will present a corporate overview at the 2021 RBC Capital Markets Global Healthcare Virtual Conference on May 19 at 9:10 a.m. ET and at the Oppenheimer Rare & Orphan Disease Summit on May 21 at 8:15 a.m. ET. Both presentations will highlight Gain's innovative drug discovery approach using its SEE-Tx™ platform to target allosteric binding sites, addressing challenging disorders linked to protein misfolding. Webcast links for the events are available on the company’s website.
Gain Therapeutics, Inc. (Nasdaq: GANX) has successfully completed its IPO, raising approximately $46 million in gross proceeds. The company has appointed four independent board members to enhance leadership and signed a collaboration agreement with Zentalis Pharmaceuticals to develop cancer treatments. Positive pre-clinical data was presented at the WorldSymposium™. For Q1 2021, the company reported net loss of $2.45 million with cash reserves of $46.59 million.
Gain Therapeutics, Inc. (NASDAQ: GANX) announced promising pre-clinical data from its GBA1 Parkinson's disease program at the IAPRD World Congress. The data highlights the potential of their Structurally Targeted Allosteric Regulators (STARs), which stabilize and restore activity of mutated GCase, leading to decreased levels of phosphorylated and aggregated α-synuclein. Key candidates GT-02287 and GT-02329 were effective in reversing neurodegeneration in animal models, suggesting a new therapeutic avenue for GBA1-related Parkinson's disease. The research was recognized as one of the top 10 abstracts presented at the conference.
Gain Therapeutics, Inc. (NASDAQ: GANX) announced its CEO, Eric Richman, will present at the B. Riley Securities’ Virtual Neuroscience Conference on April 28-29 at 4:00 p.m. ET. The company focuses on innovative drug discovery using its SEE-Tx™ platform to identify allosteric binding sites for challenging disorders linked to protein misfolding. Since its establishment in 2017, Gain has secured funding from notable organizations, including The Michael J. Fox Foundation and Eurostars-2 program. For more details, visit Gain Therapeutics.
Gain Therapeutics, Inc. (NASDAQ: GANX) announced its STAR candidate for Parkinson's disease has been selected among the 10 Best Abstracts at the IAPRD 2021 World Congress. The poster presentation, led by Roberto Maj, Pharm.D., showcases the potential of the company's structurally targeted allosteric regulators (STARs) to improve motor deficits in an in vivo model of Parkinson's disease. The conference will be held virtually from May 1-4, 2021, and the presentation will remain accessible throughout the event.
Gain Therapeutics, Inc. (NASDAQ: GANX) announced a multi-target collaboration with Zentalis Pharmaceuticals (NASDAQ: ZNTL) to identify new oncology drug targets using its proprietary SEE-Tx computational platform. This technology employs supercomputers to analyze protein structures for novel binding sites, enhancing drug discovery. Gain's CEO highlighted Zentalis' expertise in cancer treatments as a key asset for validating the SEE-Tx platform. This partnership aims to address challenges in cancer treatment through innovative target identification.
Gain Therapeutics, Inc. has successfully closed its initial public offering (IPO) of 3,636,364 shares of common stock, including the full exercise of the underwriters’ overallotment option for an additional 545,454 shares at a public offering price of $11.00 each. The gross proceeds from this offering amount to approximately $46 million, prior to deductions for underwriting discounts and expenses. Gain's shares are traded on the Nasdaq Global Market under the symbol GANX. The registration statement for this offering was made effective by the SEC on March 17, 2021.
Gain Therapeutics, Inc. has priced its initial public offering (IPO) at $11.00 per share, offering 3,636,364 shares under the symbol 'GANX'. Trading is set to commence on March 18, 2021, with the offering expected to close on March 22, 2021, subject to customary conditions. Underwriters hold a 30-day option to purchase an additional 545,454 shares. The SEC declared the registration statement effective on March 17, 2021. Gain Therapeutics aims to transform drug discovery with its See-Tx™ platform, targeting challenging disorders linked to protein misfolding.